Scott Probst

  PhotoScott Probst has worked as a process engineer at Bayer’s Berkeley site for over 13 years supporting Kogenate® manufacturing and life cycle projects. Kogenate® FS is a protein therapeutic for treatment of hemophilia A. Scott has engaged in capital project, process mapping, and process optimization activities, and he has considerable experience organizing and leading FMEA-style risk assessments for identifying and mitigating GMP risks. Since August 2010, Scott has been a Bayer representative on the BioPhorum Operations Group Area Classifications team. That team published a paper entitled “Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances” which appeared in the August 2011 edition of Biopharm International. Scott was one of the paper’s co-authors. (FR Sept. Brussels 2012)